Market reactionShares fell 10% on Nov 5.
Elicio Therapeutics develops ELI-002 7P (camupepimut), a vaccine against mutant KRAS cancers; its Phase 2 in pancreatic cancer missed its primary endpoint, and it is not approved.
ELI-002 7P, a vaccine against mutant KRAS, missed its primary disease-free survival endpoint in the Phase 2 AMPLIFY-7P trial in resected pancreatic cancer (HR 0.85). Subgroups, including R0-resected and ctDNA-negative patients, looked better, but those analyses are not confirmatory. Elicio plans a Phase 3 subject to financing and a Phase 1 with a RAS inhibitor in metastatic disease in the fourth quarter. Cash of $23.5 million lasts into the first quarter of 2027.
Thesis checklist
1 risk needs attention
Why it is in this state
The evidence, what would weaken it and the source filing
Why it is in this state
The evidence, what would weaken it and the source filing
Why it is in this state
The evidence, what would weaken it and the source filing
Next decision point
Tests: Cash lasts to new data
Does Elicio raise money or find a partner before cash runs out in early 2027?
Strong, inconclusive and weak outcomes
What to look for in the result and how each would move the checklist
Price and material events
Select an event marker to read the update below. Marker colors show Thesis status.
Elicio's pancreatic cancer vaccine missed its Phase 2 goal; cash lasts into early 2027
AMPLIFY-7P ITT miss collapses adjuvant PDAC thesis; R0 subgroup and metastatic CRs remain contingent on Q1 2027 financing
ELI-002 7P's Phase 3 in R0-resected PDAC hinges on whether a post-hoc subgroup signal survives prospective testing and whether financing materializes
ELI-002's AMPLIFY-7P Phase 2 DFS readout will determine whether a KRAS neoantigen vaccine can reduce recurrence in resected PDAC
About this history: every entry shows when the Thesis moved and what it said. The reasoning behind each move (the evidence, the analysis and the source filing) and the earnings write-ups are part of a subscription.
Dates, trials and completed outcomes are open to everyone. What each upcoming milestone hinges on is part of a subscription.
Disease areas: Gastrointestinal cancers, Other cancers
Catalyst calendar · Upcoming FDA decisions · Thesis changes
Competitive landscape
4 peers tracked
Cash: Market-data provider estimate; measurement period unavailable.
Debt: Market-data provider estimate; a complete comparable filing balance is unavailable.
Quarterly burn: Estimated from trailing free cash flow; measurement period unavailable.
Net cash and estimated runway require verified matching measurement periods. Missing debt components are not assumed to be zero.
Runway: No underlying guidance available.